The company previously reported data that suggests two doses of its capsid viruslike particle (cVLP) COVID-19 vaccine candidate (ABNCoV2) led to more than fiftyfold higher titers of neutralizing antibodies against the wild-type (Wuhan) virus when compared to titers measured in convalescent human samples, and that this translated into protection from a challenge with wild-type virus.

Most recently, a neutralization test of samples from the study has confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African), the company stated in a release.

Bavarian plans on starting a phase II trial in the second quarter of 2021 to look at the ability of ABNCoV2 to boost existing immunity through prior vaccination and create a more durable immune response that could protect against current circulating COVID-19 variants.

VBI touts positive preclinical COVID-19 vaccine data
Preclinical data suggest positive results from a COVID-19 vaccine candidate based on enveloped viruslike particle technology from VBI Vaccines (VBI).

Iqvia debuts clinical data analytics intelligence platform
Iqvia has debuted a clinical data analytics intelligence platform to accelerate vaccine development and drug discovery.

Following review, FDA lifts J&J COVID-19 vaccine pause
Johnson & Johnson's COVID-19 vaccinations are set to resume in the U.S. following a decision by the U.S. Food and Drug Administration (FDA) and the...

Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Naturally occurring molecule helps SARS-CoV-2 evade neutralizing antibodies
Researchers have identified naturally occurring molecules that are created from the breakdown of hemoglobin and block the binding of a subset of human...